News Column

Patent Issued for Combination of Protein Vaccine and Mesenchymal Stem Cells for Treating Cancer

July 21, 2014



By a News Reporter-Staff News Editor at Cancer Vaccine Week -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Deng, Win-Ping (Taipei, TW); Chang, Hsiu-Kang (Taipei, TW); Wei, Hung-Chien (Taipei, TW); Wu, Tsang-Hsien Alexander (Taipei, TW), filed on July 27, 2010, was published online on July 8, 2014 (see also HealthBanks Biotech Co., Ltd.).

The assignee for this patent, patent number 8771705, is HealthBanks Biotech Co., Ltd. (Taipei, TW).

Reporters obtained the following quote from the background information supplied by the inventors: "Despite advances in both clinical and basic research dedicated to reducing mortality rates and improving survival, cancer remains the leading cause of death among patients under 85 years of age in the United States. Most deaths from cancer do not result from the primary tumor but rather from the later metastasis. As a result, systemic therapy has become an essential component of metastatic cancer management. Systemic therapy has been limited to chemotherapy and biologic response modifiers. While new therapeutic agents like docetaxel, pernetrexed and erlotinib have been demonstrated as being effective in treating patients with advanced lung cancer, clinical responses to treatment and improved survival have been modest. The limited success of systemic chemotherapy thus underscores the need in developing adjunctive therapies.

"Cancer vaccine therapy appears to be an attractive approach for cancer treatment because of its potential in eradicating systemic tumors at multiple sites and specificity in discriminating normal cells from neoplastic cells. Unlike most vaccines for infectious agents, the goal of cancer vaccination is therapeutic and this can be achieved by activating immune responses against tumor antigens. The immune response can be crudely divided into either antibody responses or T-cell responses. Antibodies recognize and bind to conformational determinants on cell surface proteins, and can kill the cell by either antibody-dependent cellular cytotoxicity or complement-mediated cell lysis. Conversely, T cells recognize small peptides presented on the cell surface on major histocompatibility (MHC) antigens, and T-cell activation requires a co-stimulatory signal which is usually present on the cell surface of antigen-presenting cells. However, attempts to exploit the immune system as a therapeutic strategy in cancer treatment have to overcome the host's inability to develop effective endogenous immunity against cancer.

"The notion of directing the immune response towards a selected antigen should give potentially greater control of the immune response. However tumor-associated antigens have not been identified for most tumors, and where these have been identified, they may not be the most potent antigens involved in the rejection of that particular tumor, so that vaccine design may be suboptimal.

"Therefore, a heretofore unaddressed need exists in the art to address the aforementioned deficiencies and inadequacies, especially in connection with antigen-specific cancer vaccines."

In addition to obtaining background information on this patent, NewsRx editors also obtained the inventors' summary information for this patent: "In one aspect, the invention relates to a method for inhibiting growth and/or metastasis of a tumor in a mammal. The method comprises:

"administering to a mammal in need thereof an effective amount of stem cells comprising a transgene encoding at least one oncogenic protein, wherein the stem cells are immortal and show no signs of neoplastic transformation;

"administering to the mammal a vaccine composition comprising an effective amount of at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one oncogenic protein;

"allowing the at least one immunogenic protein to elicit the at least one antibody specific against the at least one oncogenic protein in the mammal; and

"allowing the elicited at least one antibody to induce tumor cell death and thereby inhibiting growth and/or metastasis of the tumor in the mammal.

"In another aspect, the invention relates to a method for inhibiting growth and/or metastasis of a tumor in a mammal, which comprises:

"administering to a mammal in need thereof an effective amount of stem cells comprising a transgene encoding at least one HPV Envelope protein selected from the group consisting of E7, E6 and a combination thereof, wherein the stem cells are immortal and show no signs of neoplastic transformation;

"administering to the mammal a vaccine composition comprising at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one HPV protein selected from the group consisting of E7, E6 and a combination thereof;

"allowing the at least one immunogenic protein to elicit the at least one antibody specific against the at least one HPV protein in the mammal; and

"allowing the elicited at least one antibody to induce tumor cell death and thereby inhibiting growth and/or metastasis of the tumor in the mammal.

"Further in another aspect, the invention relates to a therapeutic kit for inhibiting growth and/or metastasis of a tumor in a mammal. The kit comprises: a) stem cells comprising a transgene encoding at least one HPV protein selected from the group consisting of E7, E6 and a combination thereof, wherein the stem cells are immortal and show no sign of neoplastic transformation; b) a vaccine composition comprising at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one HPV protein selected from the group consisting of E7, E6 and a combination thereof; and c) a package insert containing printed instructions for performing a method for inhibiting growth and/or metastasis of a tumor in a mammal as aforementioned.

"Yet in another aspect, the invention relates to a therapeutic kit for inhibiting growth and/or metastasis of a tumor in a mammal, which comprises: a) stem cells comprising a transgene encoding at least one oncogenic protein, wherein the stem cells are immortal and show no sign of neoplastic transformation; b) a vaccine composition comprising an effective amount of at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one oncogenic protein; and c) a package insert containing printed instructions for performing a method for inhibiting growth and/or metastasis of a tumor in a mammal as aforementioned.

"These and other aspects will become apparent from the following description of the preferred embodiment taken in conjunction with the following drawings, although variations and modifications therein may be affected without departing from the spirit and scope of the novel concepts of the disclosure.

"The accompanying drawings illustrate one or more embodiments of the invention and, together with the written description, serve to explain the principles of the invention. Wherever possible, the same reference numbers are used throughout the drawings to refer to the same or like elements of an embodiment."

For more information, see this patent: Deng, Win-Ping; Chang, Hsiu-Kang; Wei, Hung-Chien; Wu, Tsang-Hsien Alexander. Combination of Protein Vaccine and Mesenchymal Stem Cells for Treating Cancer. U.S. Patent Number 8771705, filed July 27, 2010, and published online on July 8, 2014. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8771705.PN.&OS=PN/8771705RS=PN/8771705

Keywords for this news article include: Antibodies, Antigens, Therapy, Oncology, Immunology, Blood Proteins, Cancer Vaccines, Immunoglobulins, Biological Factors, Stem Cell Research, Biological Products, Mesenchymal Stem Cells, HealthBanks Biotech Co. Ltd..

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Vaccine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters